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Objective: To provide quick and accurate clinical diagnostic tools those are currently not 
available leading to improper management of colorectal cancer (CRC) patients. Methods: The 
metabolomic profiles of 10 CRC patients treated with 5-fluorouracil and 24 healthy 
volunteers were analysed. The subjects were genotyped for UGT1A1*28, DPYD 1896 T>C 
and DPYD*5. Results: Our results show alterations in the metabolism of bile acid, glycolysis 
and fatty acid in patients. The distinctive metabolite profiles established using PLSDA 
identify several biomarkers for diagnostic use in clinical settings. The predictive PLSDA 
model revealed 100% accuracy of metabolites differentiating CRC patients and healthy 
volunteers. In addition, the metabolic profiles associated with different genotypes of DPYD 
and UGT1A1 explains the impact of genetic variation on differential drug responses. 
Conclusion: Pharmacogenetics and metabolomics profiles are potential platforms for more 
comprehensive monitoring of patient's disease progress and drug response. Further study is 
however needed to validate the use of biomarkers identified. 
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